By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Peregrine Pharmaceuticals, Inc. 

14272 Franklin Avenue
Suite 100
Tustin  California  92780  U.S.A.
Phone: 714-508-6000 Fax: 714-838-5817



AVANIR Pharmaceuticals 

Company News
Peregrine (PPHM) Release: New Preclinical Data Presented At SITC Annual Meeting Highlight Bavituximab’s Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors In Breast Cancer And Melanoma 11/9/2015 1:00:37 PM
AstraZeneca PLC (AZN) And Peregrine (PPHM) Expand Ongoing Immuno-Oncology Collaboration To Include Phase Il Lung Cancer Combination Clinical Trial 10/15/2015 11:58:51 AM
Peregrine (PPHM) Presents Data At Annual Immunotherapy And Vaccine Summit (IMVACS) Supporting Ability Of Bavituximab To Mediate Anti-Tumor T Cell Responses Across Multiple Tumor Types 8/26/2015 10:57:07 AM
AstraZeneca PLC (AZN) Inks Fourth Immuno-Oncology Deal This Year, Strikes Pact with Peregrine (PPHM) to Study Combo Therapy 8/26/2015 6:43:34 AM
AstraZeneca PLC (AZN) and Peregrine (PPHM) Forge Immunotherapy Cancer Tie-Up 8/24/2015 6:25:56 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Reports Fourth Quarter And Year-End Fiscal Year 2015 Financial Results And Recent Developments 7/15/2015 7:18:58 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Declares Quarterly Dividend On Its Series E Convertible Preferred Stock 6/5/2015 7:31:06 AM
ASCO15: Data Presentations At ASCO Demonstrate The Ability Of Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab To Activate Tumor Targeting Immune Cells In PD-L1 Negative NSCLC Tumors 6/1/2015 8:52:42 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Provides Update On Planned Expansion Of Bavituximab Clinical Program 6/1/2015 8:14:36 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Enters Into Research Collaboration To Investigate Novel PS-Targeting Immunotherapy Combinations 5/29/2015 8:51:41 AM